Showing 921 - 933 results of 933 for search '"Virology"', query time: 0.04s Refine Results
  1. 921
  2. 922

    Factors influencing the unexpected measles outbreak of 2023 in Colombo, Sri Lanka by Kasunee Kalubowila, Chandana Gajanayake

    Published 2025-01-01
    “…Cases were confirmed based on serological, virological, clinical or epidemiological criteria, with incomplete data revisited to ensure accuracy. …”
    Get full text
    Article
  3. 923

    RETRACTED ARTICLE: Extracorporeal membrane oxygenation support for SARS-CoV-2: a multi-centered, prospective, observational study in critically ill 92 patients in Saudi Arabia by Saad Alhumaid, Abbas Al Mutair, Header A. Alghazal, Ali J. Alhaddad, Hassan Al-Helal, Sadiq A. Al Salman, Jalal Alali, Sana Almahmoud, Zulfa M. Alhejy, Ahmad A. Albagshi, Javed Muhammad, Amjad Khan, Tarek Sulaiman, Maha Al-Mozaini, Kuldeep Dhama, Jaffar A. Al-Tawfiq, Ali A. Rabaan

    Published 2021-12-01
    “…Results ECMO use was associated with higher in-hospital mortality (40.2% vs. 48.9%; p = 0.000); lower COVID-19 virological cure (41.3% vs 14.1%, p = 0.000); and longer hospitalization (20.2 days vs 29.1 days; p = 0.000), ICU stay (12.6 vs 26 days; p = 0.000) and mechanical ventilation use (14.2 days vs 22.4 days; p = 0.000) compared to non-ECMO group. …”
    Get full text
    Article
  4. 924

    Coexisting patterns and significance of serum HBV RNA and HBV DNA in patients with treatment-naïve chronic hepatitis B virus infection by Kun-yan Hao, Kun-yan Hao, Ye Fan, Yi-qing Zhang, Yue-cheng Yu

    Published 2025-01-01
    “…AimThe study aimed to explore the coexisting patterns and assess the significance of serum hepatitis B virus (HBV) RNA and traditional virological biomarkers in patients with antiviral treatment-naïve chronic hepatitis B virus (HBV) infection.MethodsSerum HBV RNA, HBV DNA, hepatitis B surface antigen (HBsAg), and hepatitis B envelope antigen (HBeAg) levels were measured and compared in patients with chronic hepatitis B virus infection. …”
    Get full text
    Article
  5. 925

    Cytokines in Liver Cirrhosis (Their Importance in Assessing Activity and Decompensation) by G. K. Mirodzhov, S. D. Pulatova

    Published 2023-11-01
    “…The material of the study was the data of clinical-instrumental, biochemical, virological studies of 109 patients with liver cirrhosis of various etiologty, who were hospitalized in the clinic of the Institute of Gastroenterology (Dushanbe, Republic of Tajikistan). …”
    Get full text
    Article
  6. 926

    Sex differences in epigenetic ageing for older people living with HIVResearch in context by Carrie D. Johnston, Alina P.S. Pang, Eugenia L. Siegler, Charlene Thomas, Chelsie O. Burchett, Mia Crowley, Rochelle O'Brien, Lishomwa C. Ndhlovu, Marshall J. Glesby, Michael J. Corley

    Published 2025-03-01
    “…Despite evidence indicating sex differences in clinical, immunological, and virological measures, females have been underrepresented in most HIV epigenetic studies. …”
    Get full text
    Article
  7. 927

    Adherence to Viral Load Testing Guidelines, Barriers, and Associated Factors Among Persons Living with HIV on ART in Southwestern Uganda: a Mixed-Methods Study. by Lubega, Polly, Nalugya, Sylivia Juliet, Kimuli, Angella Namyalo, Twinokusiima, Majoreen, Khasalamwa, Mercy, Kyomugisa, Richard, Kabami, Jane, Owaraganise, Asiphas

    Published 2024
    “…Background: Uganda adapted Viral load (VL) testing for monitoring HIV treatment success and virologic failure. However, there is a paucity of data on how the VL testing guidelines are followed in practice in HIV clinics. …”
    Get full text
    Article
  8. 928
  9. 929

    Peer-assisted telemedicine hepatitis-C treatment for people who use drugs in rural communities: a mixed methods study by Kim Hoffman, Gillian Leichtling, Sarah Shin, Andrew Seaman, Tonhi Gailey, Hunter C. Spencer, P. Todd Korthuis

    Published 2025-02-01
    “…The Oregon HOPE TeleHCV study randomized PWUD living with HCV in rural Oregon to peer-facilitated and streamlined telemedicine HCV treatment (Peer TeleHCV) versus enhanced usual care (EUC) and assessed sustained virologic response at 12 weeks post treatment (SVR12). …”
    Get full text
    Article
  10. 930
  11. 931

    Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamid... by Bruno Emond, Carmine Rossi, Aurélie Côté-Sergent, Keith Dunn, Patrick Lefebvre, Marie-Hélène Lafeuille, Prina Donga

    Published 2021-06-01
    “…**Methods:** The Symphony Health, IDV® database (July 17, 2017 – September 30, 2019) was used to identify treatment naïve or virologically suppressed stable switchers who initiated DRV/c/FTC/TAF or BIC/FTC/TAF (index date) on or after July 17, 2018, were ≥18 years of age on the index date, and had ≥12 months of continuous clinical activity pre-index (baseline period). …”
    Get full text
    Article
  12. 932

    Are We Aware of Hepatitis C Infection? HCV Results from the Tertiary Reference Center in the Aegean Region from Turkey by Gözde Derviş Hakim, Pınar Şamlıoglu, Murat Aysin, Taner Kara, Şükran Köse

    Published 2024-01-01
    “…With the advent of direct-acting antiviral agents, the rate of sustained virological response in the treatment of hepatitis C virus (HCV) infection has reached 100%. …”
    Get full text
    Article
  13. 933

    Long-term outcome in people who use drugs successfully treated for hepatitis C infection with glecaprevir/pibrentasvir by Shana Yi, David Truong, Brian Conway

    Published 2024-12-01
    “…In the GRAND PLAN, we documented sustained virological response post-treatment Week12 (SVR12) in 108/117 (92.3 %) individuals (108/111 (mITT) or 97.3 % of those reaching the SVR12 timepoint) receiving an 8-week course of glecaprevir/pibrentasvir (G/P), with almost all using fentanyl and over half being unstably housed. …”
    Get full text
    Article